16th June 2021
Resistell AG announces start of Performance Evaluation Study
Resistell AG has started the Performance Evaluation Study (PES) of its groundbreaking nanomotion technology at Lausanne University Hospital (CHUV)
15th February 2021
Faster to the right antibiotic treatment - Resistell in Schweizerische Ärztezeitung
How do you find the most effective antibiotic for a patient as quickly as possible? The start-up "Resistell" has developed a new type of test for antibiotic resistance. Read more about this test in Schwizerische Ärztezeitung.
11th February 2021
International Day of Women and Girls in Science - European Innovation Council interview with Danuta Cichocka
On the International Day of Women and Girls in Science, European Innovation Council invited Danuta Cichocka, Resistell CEO, the female scientist and entrepreneur, to share her story about her passion in life science in an interview.
10th February 2021
Aus welchem Holz sind Gründerinnen und Gründer geschnitzt?
Die Covid-Pandemie hat alle Bereiche des Lebens erfasst. Auch die Startup- und Gründerszene musste mit der Situation umgehen und unter erschwerten Bedingungen die Projekte weiter führen und antreiben. Gleichzeitig aber hat Corona als Katalysator gewirkt für disruptive Ideen, für Innovation und Unternehmergeist.
7th January 2021
Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.
The Muttenz-based biotech startup proposes an alternative to culture-based antibiograms, the current gold standard in antibiotic susceptibility testing. The EPFL spin-off offers a diagnostic device, the rapid AST method, which is based on the detection of movement caused by living bacterial cells. The new method reduces the time taken to get a result from days to minutes, shows which specific antibiotic is effective against the bacteria, and significantly improves the chances of patients’ survival.